A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women.

T. Ueland, Scott Wilson, A. Islam, B.H. Mullin, A. Devine, J. Bollerslev, Kun Zhu, Richard Prince

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective  To investigate the role of serum osteoprotegerin (OPG) and OPG gene polymorphisms in relation to cardiovascular (CV) and all-cause mortality in elderly women.Background  The OPG/RANK/RANKL plays a vital role in bone cell biology. It has also been detected in myocardial tissue and atherosclerotic plaques. In some population studies, OPG and OPG gene polymorphisms have been associated with CV disease risk.Design, measurements and results  In an 8·5-year cohort population study of 1333 postmenopausal women mean age 75·2 ± 2·7 years, serum OPG concentrations above the median were associated with an increased risk of all-cause [odds ratio (OR) 1·39 (1·04–1·85)], and in particular CV mortality [OR 1·83 (1·10–3·05)], before and after adjusting for age, BMI, treated hypertension, diabetes, hypercholesterolemia, previous HRT use, calcium supplementation and smoking. Genotyping the OPG gene did not provide further information on the association between OPG and CV risk or mortality events.Conclusions  Raised osteoprotegerin appears to be an independent risk factor for total and CV death and thus has potential as a useful biomarker of risk as well as a potential target for therapeutic intervention.
Original languageEnglish
Pages (from-to)828-833
JournalClinical Endocrinology
Volume71
Issue number6
DOIs
Publication statusPublished - 2009

Fingerprint

Osteoprotegerin
Cohort Effect
Cohort Studies
Mortality
Serum
Genes
Odds Ratio
Atherosclerotic Plaques
Hypercholesterolemia
Population
Cell Biology
Cardiovascular Diseases
Biomarkers
Smoking
Hypertension
Calcium
Bone and Bones

Cite this

@article{908cfeac14144c0ca27cc7feeec07a84,
title = "A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women.",
abstract = "Objective  To investigate the role of serum osteoprotegerin (OPG) and OPG gene polymorphisms in relation to cardiovascular (CV) and all-cause mortality in elderly women.Background  The OPG/RANK/RANKL plays a vital role in bone cell biology. It has also been detected in myocardial tissue and atherosclerotic plaques. In some population studies, OPG and OPG gene polymorphisms have been associated with CV disease risk.Design, measurements and results  In an 8·5-year cohort population study of 1333 postmenopausal women mean age 75·2 ± 2·7 years, serum OPG concentrations above the median were associated with an increased risk of all-cause [odds ratio (OR) 1·39 (1·04–1·85)], and in particular CV mortality [OR 1·83 (1·10–3·05)], before and after adjusting for age, BMI, treated hypertension, diabetes, hypercholesterolemia, previous HRT use, calcium supplementation and smoking. Genotyping the OPG gene did not provide further information on the association between OPG and CV risk or mortality events.Conclusions  Raised osteoprotegerin appears to be an independent risk factor for total and CV death and thus has potential as a useful biomarker of risk as well as a potential target for therapeutic intervention.",
author = "T. Ueland and Scott Wilson and A. Islam and B.H. Mullin and A. Devine and J. Bollerslev and Kun Zhu and Richard Prince",
year = "2009",
doi = "10.1111/j.1365-2265.2009.03605.x",
language = "English",
volume = "71",
pages = "828--833",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "John Wiley & Sons",
number = "6",

}

A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women. / Ueland, T.; Wilson, Scott; Islam, A.; Mullin, B.H.; Devine, A.; Bollerslev, J.; Zhu, Kun; Prince, Richard.

In: Clinical Endocrinology, Vol. 71, No. 6, 2009, p. 828-833.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women.

AU - Ueland, T.

AU - Wilson, Scott

AU - Islam, A.

AU - Mullin, B.H.

AU - Devine, A.

AU - Bollerslev, J.

AU - Zhu, Kun

AU - Prince, Richard

PY - 2009

Y1 - 2009

N2 - Objective  To investigate the role of serum osteoprotegerin (OPG) and OPG gene polymorphisms in relation to cardiovascular (CV) and all-cause mortality in elderly women.Background  The OPG/RANK/RANKL plays a vital role in bone cell biology. It has also been detected in myocardial tissue and atherosclerotic plaques. In some population studies, OPG and OPG gene polymorphisms have been associated with CV disease risk.Design, measurements and results  In an 8·5-year cohort population study of 1333 postmenopausal women mean age 75·2 ± 2·7 years, serum OPG concentrations above the median were associated with an increased risk of all-cause [odds ratio (OR) 1·39 (1·04–1·85)], and in particular CV mortality [OR 1·83 (1·10–3·05)], before and after adjusting for age, BMI, treated hypertension, diabetes, hypercholesterolemia, previous HRT use, calcium supplementation and smoking. Genotyping the OPG gene did not provide further information on the association between OPG and CV risk or mortality events.Conclusions  Raised osteoprotegerin appears to be an independent risk factor for total and CV death and thus has potential as a useful biomarker of risk as well as a potential target for therapeutic intervention.

AB - Objective  To investigate the role of serum osteoprotegerin (OPG) and OPG gene polymorphisms in relation to cardiovascular (CV) and all-cause mortality in elderly women.Background  The OPG/RANK/RANKL plays a vital role in bone cell biology. It has also been detected in myocardial tissue and atherosclerotic plaques. In some population studies, OPG and OPG gene polymorphisms have been associated with CV disease risk.Design, measurements and results  In an 8·5-year cohort population study of 1333 postmenopausal women mean age 75·2 ± 2·7 years, serum OPG concentrations above the median were associated with an increased risk of all-cause [odds ratio (OR) 1·39 (1·04–1·85)], and in particular CV mortality [OR 1·83 (1·10–3·05)], before and after adjusting for age, BMI, treated hypertension, diabetes, hypercholesterolemia, previous HRT use, calcium supplementation and smoking. Genotyping the OPG gene did not provide further information on the association between OPG and CV risk or mortality events.Conclusions  Raised osteoprotegerin appears to be an independent risk factor for total and CV death and thus has potential as a useful biomarker of risk as well as a potential target for therapeutic intervention.

U2 - 10.1111/j.1365-2265.2009.03605.x

DO - 10.1111/j.1365-2265.2009.03605.x

M3 - Article

VL - 71

SP - 828

EP - 833

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -